Cargando…

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease

Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muhlack, Siegfried, Müsch, Patricia, Konietzka, Sandra, Woitalla, Dirk, Przuntek, Horst, Müller, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967140/ https://www.ncbi.nlm.nih.gov/pubmed/27721359 http://dx.doi.org/10.3390/pharmaceutics2030313

Ejemplares similares

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
por: Park, Sangmin, et al.
Publicado: (2023)

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease
por: Lin, Iris, et al.
Publicado: (2023)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson’s disease
por: Ionescu, Mihaela Ileana
Publicado: (2020)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

Emerging Immunotherapies for Parkinson Disease
por: Zella, Samis M. A., et al.
Publicado: (2018)

Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson’s Disease
por: Pesch, Beate, et al.
Publicado: (2019)

Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms
por: Hellwig, Kerstin, et al.
Publicado: (2004)

Discovery of amantadine formate: Toward achieving ultrahigh pyroelectric performances in organics
por: Zhou, Junyan, et al.
Publicado: (2022)

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study
por: Hammond, Flora M., et al.
Publicado: (2015)

Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study
por: Khlebtovsky, Alexander, et al.
Publicado: (2019)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

Parkinson’s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement
por: Hartelt, Elke, et al.
Publicado: (2020)

Amantadine Ameliorates Dopamine-Releasing Deficits and Behavioral Deficits in Rats after Fluid Percussion Injury
por: Huang, Eagle Yi-Kung, et al.
Publicado: (2014)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Paraneoplastic Chorea Managed with Intravenous Amantadine
por: Doher, Nicholas, et al.
Publicado: (2019)

Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses
por: Nguyen, Jack T., et al.
Publicado: (2012)

COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2022)

Less car, more bicycle? Generation Y as pioneers of changing everyday mobility in Germany
por: Konietzka, Dirk, et al.
Publicado: (2023)

The Effect of Oral Administration of Amantadine on Neurological Outcome of Patients With Diffuse Axonal Injury in ICU
por: Abbasivash, Rahman, et al.
Publicado: (2019)

Amantadine therapy for Parkinson’s Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature
por: Cennamo, Michela, et al.
Publicado: (2022)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
por: Richter, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fdheoa96qhrharduup1k0kqu2g